Posted by Alan on October 11, 2002, at 0:57:04
In reply to Re: AD's vs. Bzds for Anxiety disorders, posted by jane d on October 10, 2002, at 23:28:50
> > Would you please elaborate further about the need to focus on AD's at the expense of Bzd's in the treatment of anxiety disorders....causing doctors to mistakenly offer only AD monotherapy instead of both BZD monotherapy AND AD monotherapy on equal footing for their patients' clinical trials?
> >
>
> Alan,
>
> Pharmrep has said he is a sales representative for a company, not a representative of the industry as a whole. It's not reasonable to expect him to be able to answer questions about overall drug development or marketing policies. Probably you and the other posters on this board that have a personal interest in bzds know as much as anybody else.
>
> Jane
============================================Why don't we let the parmecutical representative speak for themselves? They are well armed to field any questions about their new medications in relation to others - that's what salesman do.
Someone as well versed in psychotropics and their chemistry in the treatment of anxiety disorders - as I see technical information, statistics, etc cited about how effective Lexapro is - in medical parlance that would make the average consumer's head spin, why would it be unreasonable to ask why they think this medication is more effective for treating anxiety disorders than the well established bzds?
I'm sure that such sophisticated knowledge of the disorder, symptomology, and side effects during treatment would qualify them (if some think only marginally) to comment on why they think their product is more effective in the treatment of anxiety disorders than bzds.
After all, as they have shown, it is their specific area of expertise. No one is asking for a commentary or analysis of the pharm industry in general here as I understand it...
Alan
poster:Alan
thread:109458
URL: http://www.dr-bob.org/babble/20021006/msgs/123181.html